Haematology 2018

PROGRESSION-FREE SURVIVAL (ALL INHL PATIENTS): ON STUDY VS. LAST PRIOR THERAPY

Median PFS (months) On study: 11.0 Last prior therapy: 4.6

100

75

50

PFS (%)

25

0

0

6

12

18

24

30

36

42

Time from start of idelalisib (months)

125

60

33

22

12

4

Patients at risk, n

125

40

14

9

5

2

1

Gopal A et al. ASH 2014, Abstract #1708